Actinium Pharmaceuticals Inc. recently presented data on ATNM-400, a new antibody radioconjugate that uses actinium-225 (Ac-225) to target a non-prostate-specific member antigen (PSMA) protein that is frequently overexpressed in several tumor types, including prostate cancer.
The U.S. FDA has cleared Rocket Pharmaceuticals Inc.’s IND application for RP-A701, an AAVrh.74-based gene therapy candidate for the treatment of BAG3-associated dilated cardiomyopathy (BAG3-DCM), a severe form of heart failure.
Many cancers involve upregulation of Aurora kinase B, which helps deregulate normal cell cycling to drive tumor proliferation. The kinase should therefore be a good therapeutic target, yet no small-molecular inhibitor has been clinically approved despite more than two decades of effort.
Abion Inc. signed a potential $1.315 billion deal with an anonymous partner June 22, granting the counterparty exclusive global rights to a preclinical claudin 3-targeting monoclonal antibody, ABN-501, and the potential to license four more protein targeting antibodies.
Muscarinic M4 receptor positive allosteric modulators are detailed in an Acadia Pharmaceuticals Inc. patent. They are reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, Huntington’s disease, Parkinson’s disease, psychosis and drug abuse and dependence.
Genep Inc. has prepared and tested Imidazole compounds acting as sodium channel protein type 8 subunit α (SCN8A; Nav1.6) blockers reported to be useful for the treatment of epilepsy.
Blossomhill Therapeutics Inc. has synthesized new indazole-based macrocyclic compounds acting as ALK tyrosine kinase receptor inhibitors potentially useful for the treatment of cancer.
Atai Therapeutics Inc. has patented new 5-HT2A receptor agonists reported to be useful for the treatment of substance abuse and dependence, treatment-resistant depression, major depression, anxiety, eating, obsessive-compulsive and stress disorder.
RSS
